Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.9735 +0.1645 (+20.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
--News Direct-- 
Via News Direct
News headline image
Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases ↗
Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga. 
Via Benzinga
News headline image
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions ↗
Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. 
Via Benzinga
News headline image
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS ↗
Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN)... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates ↗
LGVN stock earnings show Longeveron reporting a wider loss than analysts expected and missing revenue estimates. 
Via InvestorPlace
News headline image
Recap: Longeveron Q1 Earnings ↗
 
Via Benzinga
News headline image
Preview: Longeveron's Earnings ↗
 
Via Benzinga
News headline image
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes? 
Via News Direct
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?
By David Willey, Benzinga 
Via TheNewswire.com
News headline image
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes? ↗
Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2023 ↗
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free ↗
Longeveron Inc (NASDAQ: LGVN) announced new long-term follow-up data from its ELPIS I trial of Lomecel-BTM for patients with  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
News headline image
Why Is Longeveron (LGVN) Stock Up 30% Today? ↗
Longeveron (LGVN) stock is on the move Tuesday after releasing new long-term survival data from HLHS treatment Lomecel-B. 
Via InvestorPlace
News headline image
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty ↗
Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2023 ↗
Companies Reporting Before The Bell • CSI Compressco (NASDAQ:CCLP) is estimated to report earnings for its fourth quarter. • Longeveron (NASDAQ:LGVN) is expected to report earnings for its fourth... 
Via Benzinga
News headline image
Insiders Just Bought $1 Million of This Deep Value Tech Stock ↗
CEO and CFO buying is a bullish indicator... and based on new SEC filings, things are heating up for IHRT stock. Dive in here. 
Via InvestorPlace
News headline image
3 Penny Stocks That Could Rise 500% in 2023 ↗
Tilt the odds in your favor in 2023 with some of these high-potential penny stocks. The risks are high, but so are the rewards. 
Via InvestorPlace
News headline image
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug ↗
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
News headline image
Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock. ↗
Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit. 
Via InvestorPlace
News headline image
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket ↗
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million. 
Via Benzinga
News headline image
How to Find Stocks That Rise 10x ↗
Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality. 
Via InvestorPlace
News headline image
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.